Massive Bio is looking to create the world’s largest AI-enabled ‘just-in-time’ oncology site network to accelerate study recruitment – and believes that 15-20% of advanced-stage cancer patients can be enrolled in clinical trials, says CEO.
Analytical solutions provider, Cytel, launches its East On Demand system to provide small biotechs access to more flexible software for adaptive trial design.
Product Specific PTRS, Evaluate’s machine learning platform, aims to help assess the likelihood of a drug reaching the market – managing the risks of drug development.
Takeda and Sosei both have a proud heritage in Japan and recently entered a billion-dollar partnership with Sosei to discover, develop, and commercialize molecules for patients in need around the world.
It’s a lot more complicated than a simple technology – says Iqvia global head of virtual trials, who shares four lessons learned during a discussion at the company’s headquarters in Research Triangle Park.
Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.
Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.
Javara teams up with a doctor-owned medical practice to increase access to clinical trials – based on the needs of the patient, rather than the needs of big pharma, says CEO.
CordenPharma has a new CEO, Arbour Group advances plans to expand in RTP, Ashfield brings on a former Iqvia VP, and Recursion adds to its c-suite after raising $121m this month.
Growing need for validated storage capacity sees Lyophilization Services of New England complete an expansion its cGMP storage capabilities at its New Hampshire site.
Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development.
Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.
